Precigen (PGEN) and Its Competitors Critical Survey

Precigen (NASDAQ:PGEN) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Precigen to related businesses based on the strength of its earnings, dividends, valuation, institutional ownership, analyst recommendations, risk and profitability.

Valuation and Earnings

This table compares Precigen and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Precigen	$9.68 million	-$250.64 million	44.70
Precigen Competitors	$728.25 million	$12.25 million	-15.19

Precigen’s rivals have higher revenue and earnings than Precigen. Precigen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and price targets for Precigen and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1	1	4	0	2.50
Precigen Competitors	9838	15122	45436	1587	2.54

Precigen presently has a consensus price target of $13.50, indicating a potential upside of 202.01%. As a group, “Biotechnology” companies have a potential upside of 102.59%. Given Precigen’s higher possible upside, analysts plainly believe Precigen is more favorable than its rivals.

Institutional & Insider Ownership

33.5% of Precigen shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 41.4% of Precigen shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Precigen has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Precigen’s rivals have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Profitability

This table compares Precigen and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precigen	15.55%	57.93%	14.43%
Precigen Competitors	-12,357.18%	-197.96%	-30.56%

Summary

Precigen beats its rivals on 7 of the 13 factors compared.

Precigen Company Profile

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.